Johnson & Johnson (JNJ)vsYD Bio Ltd (YDES)
JNJ
Johnson & Johnson
$264.79
-1.06%
HEALTHCARE · Cap: $648.67B
YDES
YD Bio Ltd
$7.42
-2.50%
HEALTHCARE · Cap: $539.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 7901861% more annual revenue ($97.93B vs $1.24M). YDES leads profitability with a 24.7% profit margin vs 21.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
YDES
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.2%
Fair Value
$141.39
Current Price
$264.79
$123.40 premium
Intrinsic value data unavailable for YDES.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Revenue surging 314.9% year-over-year
Conservative balance sheet, low leverage
Keeps 25 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -66.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : YDES
The strongest argument for YDES centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at -382.1%. Revenue growth of 314.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : YDES
The primary concerns for YDES are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while YDES is a growth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
YDES is growing revenue faster at 314.9% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 32/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →YD Bio Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?